Home > Pressrelease > Helicobacter Pylori Testing Market worth over $632mn by 2027

Helicobacter Pylori Testing Market worth over $632mn by 2027

  • Published Date: December 13, 2021

Helicobacter Pylori Testing Market size is set to surpass USD 632 million by 2027, according to a new research report by Global Market Insights Inc.
 

The increasing risk of helicobacter pylori (H. pylori) infection is anticipated to drive market growth globally. In the U.S., the seroprevalence studies of H. pylori indicates notable difference among cohorts with lower socioeconomic status. Further, the severe health concerns associated with the infection such as dyspepsia, gastric cancers, and peptic ulcers are projected to stimulate the demand for testing.
 

Rise in prevalence of gastric ulcer to propel the market expansion

People with H. pylori infection have a greater risk of gastric ulcers as the bacteria damage the protective lining of the stomach as well as the intestine. The testing allows the detection of bacteria in the digestive tract and diagnoses the infection that helps in evaluating appropriate treatment. Moreover, benefits associated with testing such as reliability in gastric ulcer screening and reduced severity of infection with a better diagnosis are forecasted to positively impact the demand for helicobacter pylori testing.
 

Recent research studies have observed that H. pylori cause the majority of gastric ulcers. The highest incidence rate in developed, as well as some developing regions, is further attributed to increased testing.  Further, changing lifestyle including unhealthy food habits is one of the factors augmenting the risk of bacterial infections. Also, increased consumption of alcohol, use of nonsteroidal anti-inflammatory drugs (NSAIDs), and smoking are some of the prominent disease-causing factors.
 

Growing adoption of non-invasive testing approach across the globe

Global Helicobacter Pylori Testing Market By Test Type

Get more details on this report - Request Free Sample PDF
 

The non-invasive test segment is predicted to witness 11.4% growth rate through 2027 led by the increase in the preference for non-invasive diagnosis, especially urea breath tests and enhanced accuracy provided by these tests. Urea breath test (UBT) has demonstrated accurate diagnosis of H. pylori infection and offers maximum sensitivity & specificity under standardized conditions.
 

In addition, epidemiological studies evaluating the efficacy of H. pylori eradication therapies are increasingly using UBT. Non-invasive techniques are highly preferred owing to minimal risk of acquired infections and cost-effectivity as compared to expensive and invasive endoscopy tests. These tests enable the clinicians to monitor eradication in clinical settings, with the possible exclusion of patients with gastric or complicated ulcers.
 

Browse key industry insights spread across 204 pages with 329 market data tables & 16 figures & charts from the report, “Helicobacter Pylori Testing Market Size By Test Type (Invasive {Histology, Rapid Urease Test (RUT), HP Culture}, Non-Invasive {Serologic Test, Urea Breath Test (UBT), Stool Antigen Test (SAT)}, By Method (Point-of-Care (POC) Test, Laboratory Based Test), By End-use (Hospitals, Clinics, Diagnostic Laboratories), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/helicobacter-pylori-testing-market
 

Increasing investment by the market players to develop safe and effective helicobacter pylori testing kits will attract a large customer pool

The laboratory-based test segment in the helicobacter pylori testing market is poised to reach more than USD 380 million by 2027 due to the laboratory-based helicobacter pylori testing provides multiple benefits including rapid diagnosis and quick results, with the minimum requirement of testing samples. Easy use, convenience, and suitability of laboratory-based tests, such as serology and ELISA for large populations will benefit the industry growth. Along with the convenience and cost, these tests offer precision, sensitivity, and specificity in large epidemiological surveys. Additionally, the availability of a broad spectrum of kits for performing these tests with proven accuracy will foster products preference in laboratories.
 

Emerging number of hospitals offering early disease diagnosis to fuel the market progression

The hospital segment is estimated to attain a CAGR of 11.6% till 2027 impelled by the availability of skilled professionals, effective diagnosis, and the rising prevalence of conditions such as gastric cancer, duodenal ulcers, and gastritis. Furthermore, the higher incidence in developed nations with sufficient healthcare infrastructure will positively impact the adoption of helicobacter pylori testing.
 

High prevalence will ultimately augment the disease diagnosis rate at hospitals. As a result, accessibility to diagnosis coupled with the rising prevalence of H. pylori infection and associated conditions will boost patient visits to hospitals, thereby accelerating the industry expansion.  Moreover, the focus on infrastructure development in emerging economies will lead to the expansion of hospitals network that will further influence the product usage. Large patient pool and increasing hospital visits owing to peptic ulcer is expected to impel the market revenue.
 

Growing demand for advanced helicobacter pylori testing in Germany will spur the business growth

Germany helicobacter pylori testing market size was USD 16 million in 2020 due to the acceptance of sedentary lifestyle that has led to the growing incidence of peptic ulcers and H. pylori infection across the region. The H. pylori infection contributing to the prevalence of such diseases will create industry progression opportunities in the country.
 

Further, continuous development and breakthroughs in helicobacter pylori testing by various players across the country have uplifted the market opportunities. This has not only led to the emergence of an innovative H. pylori diagnostic product portfolio, but also increased the demand for helicobacter pylori testing as it helps in early disease detection.
 

Companies are focusing on strategies and launch of innovative products to expand customer base

Some of the major players operating in the market are Abbott Laboratories, Avanos Corporate, Biohit Oyj, Bio-Rad Laboratories, Inc., Cardinal Health, Exalenz Bioscience Ltd., Gulf Coast Scientific, and Medline Industries, Inc. These market leaders are involved in partnerships, agreements, and acquisitions to gain an edge over their competitors.
 

Authors: Sumant Ugalmugle, Rupali Swain